Filing Details

Accession Number:
0001209191-23-011450
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-21 20:16:34
Reporting Period:
2023-02-16
Accepted Time:
2023-02-21 20:16:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1743881 Bridgebio Pharma Inc. BBIO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1780030 C Brian Stephenson C/O Bridgebio Pharma, Inc.
3160 Porter Dr., Suite 250
Palo Alto CA 94304
Secretary, Treasurer & Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-02-16 27,627 $0.00 247,156 No 4 M Direct
Common Stock Disposition 2023-02-16 9,910 $12.64 237,246 No 4 F Direct
Common Stock Disposition 2023-02-17 15,567 $12.65 221,679 No 4 S Direct
Common Stock Disposition 2023-02-17 2,150 $13.06 219,529 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2023-02-16 1,710 $0.00 1,710 $0.00
Common Stock Restricted Stock Units Disposition 2023-02-16 778 $0.00 778 $0.00
Common Stock Restricted Stock Units Disposition 2023-02-16 24,193 $0.00 24,193 $0.00
Common Stock Restricted Stock Units Disposition 2023-02-16 946 $0.00 946 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
8,549 No 4 M Direct
6,225 No 4 M Direct
96,772 No 4 M Direct
10,412 No 4 M Direct
Footnotes
  1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
  2. Includes 345 shares acquired by the Reporting Person on February 15, 2023 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
  3. Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 27,627 shares of Common Stock underlying the Reporting Person's RSUs.
  4. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 6, 2022.
  5. Represents the weighted average sale price of the shares sold from $12.04 to $13.03 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein.
  6. Represents the weighted average sale price of the shares sold from $13.04 to $13.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein.
  7. The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.
  8. The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.
  9. The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
  10. The RSUs vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/12th of the remaining underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on November 16, 2025, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.